Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III …

E Versteijne, M Suker, K Groothuis… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.

CHJ Van Eijck, E Versteijne, M Suker, K Groothuis… - 2021 - ascopubs.org
4016 Background: Preoperative chemoradiotherapy (CRT) may improve overall survival in
resectable pancreatic cancer (RPC) and borderline resectable pancreatic cancer (BRPC) …

Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled …

G Van Tienhoven, E Versteijne, M Suker… - 2018 - ascopubs.org
LBA4002 Background: Standard of care for patients with (borderline) resectable pancreatic
adenocarcinoma is resection followed by adjuvant chemotherapy. Previous studies suggest …

Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized …

E Versteijne, JL van Dam, M Suker… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline
resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial …

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a …

E Versteijne, CHJ van Eijck, CJA Punt, M Suker… - Trials, 2016 - Springer
Background Pancreatic cancer is the fourth largest cause of cancer death in the United
States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year …

Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which …

R Casadei, M Di Marco, C Ricci, D Santini… - Journal of …, 2015 - Elsevier
Objective The objective of the study is to evaluate the usefulness of neoadjuvant
chemoradiotherapy in resectable pancreatic cancer. Methods A single-center RCT of …

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic …

M Tachezy, F Gebauer, C Petersen, D Arnold, M Trepel… - BMC cancer, 2014 - Springer
Background Median OS after surgery in curative intent for non-metastasized pancreas
cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence …

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer

AG Morganti, M Massaccesi, G La Torre… - Annals of surgical …, 2010 - Springer
Purpose The objective of this study was to determine the effect on resection rate and survival
of neoadjuvant chemoradiotherapy for primarily unresectable locally advanced pancreatic …

[HTML][HTML] Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized …

I Ghanem, D Lora, N Herradón, G de Velasco… - ESMO open, 2022 - Elsevier
Background The role of neoadjuvant chemotherapy (NC) in resectable pancreatic cancer
(RPC) has yet to be defined. This review aims to analyze the benefit of NC in RPC compared …

A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer

JM Laurence, PD Tran, K Morarji, GD Eslick… - Journal of …, 2011 - Elsevier
Introduction This systematic review and meta-analysis aims to characterize the surgically
important benefits and complications associated with the use of neoadjuvant …